Human care company Elekta AB (STO:EKTAB.ST) announced on Wednesday the receipt by its Elekta Unity magnetic resonance radiation therapy (MR/RT) system of 510(k) premarket notification from the US Food and Drug Administration, clearing the technology for commercial sales and clinical use in the US.
Reportedly, Elekta Unity had received CE mark in June 2018 and has been transforming the care of cancer patients in Europe.
According to the company, with Elekta Unity, it is now feasible to develop personalised, precision radiation therapy regimens that are optimised for safety and efficacy and make radiation therapy a viable treatment option for more patients.
Also, Unity has the potential to transform how clinicians treat cancer by enabling the delivery of the radiation dose while simultaneously visualising the tumour and surrounding healthy tissue with high-quality MR images. Unity also integrates advanced tools that allow clinicians to adapt the patient's treatment to this current anatomical information within a treatment session.
Elekta offers treatment solutions and oncology informatics portfolios that are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, as well as to drive cost efficiency in clinical workflows.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT